46,392 Shares in Evolent Health, Inc $EVH Purchased by Counterpoint Mutual Funds LLC

Key Points

• Counterpoint Mutual Funds LLC purchased 46,392 shares of Evolent Health, valued at approximately $522,000, during the second quarter.
• Analysts have a consensus rating of "Buy" for Evolent Health, with Piper Sandler recently increasing their price target from $16.00 to $18.00.
• Evolent Health reported a 31.3% year-over-year decline in revenue, with earnings per share of ($0.10) for the last quarter, missing expectations.

Counterpoint Mutual Funds LLC acquired a new position in Evolent Health, Inc (NYSE:EVH - Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 46,392 shares of the technology company's stock, valued at approximately $522,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in EVH. Brighton Jones LLC purchased a new stake in Evolent Health in the 4th quarter worth about $3,927,000. ProShare Advisors LLC raised its position in Evolent Health by 49.0% in the 4th quarter. ProShare Advisors LLC now owns 32,513 shares of the technology company's stock worth $366,000 after purchasing an additional 10,698 shares during the period. State of Wyoming purchased a new stake in Evolent Health in the 4th quarter worth about $95,000. GAMMA Investing LLC raised its position in Evolent Health by 5,036.4% in the 1st quarter. GAMMA Investing LLC now owns 9,451 shares of the technology company's stock worth $90,000 after purchasing an additional 9,267 shares during the period. Finally, Rhumbline Advisers raised its position in Evolent Health by 2.1% in the 1st quarter. Rhumbline Advisers now owns 169,918 shares of the technology company's stock worth $1,609,000 after purchasing an additional 3,527 shares during the period.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on EVH shares. Piper Sandler increased their price objective on shares of Evolent Health from $16.00 to $18.00 and gave the stock an "overweight" rating in a research report on Thursday, August 28th. Truist Financial upped their target price on shares of Evolent Health from $14.00 to $16.00 and gave the stock a "buy" rating in a research note on Thursday, July 17th. BTIG Research restated a "buy" rating and issued a $20.00 target price on shares of Evolent Health in a research note on Tuesday, September 9th. JMP Securities restated a "market outperform" rating and issued a $13.00 target price on shares of Evolent Health in a research note on Friday, June 20th. Finally, Canaccord Genuity Group restated a "buy" rating and issued a $16.00 target price on shares of Evolent Health in a research note on Tuesday, September 9th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat, Evolent Health currently has an average rating of "Buy" and a consensus target price of $17.43.

Evolent Health Price Performance

Shares of EVH opened at $8.58 on Tuesday. The company has a market cap of $1.01 billion, a price-to-earnings ratio of -5.33 and a beta of 0.73. Evolent Health, Inc has a twelve month low of $7.06 and a twelve month high of $31.32. The company has a quick ratio of 1.01, a current ratio of 1.01 and a debt-to-equity ratio of 0.72. The company has a 50 day moving average of $9.48 and a two-hundred day moving average of $9.49.

Evolent Health (NYSE:EVH - Get Free Report) last announced its earnings results on Thursday, August 7th. The technology company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.20). The firm had revenue of $444.33 million during the quarter, compared to analyst estimates of $459.43 million. Evolent Health had a negative net margin of 5.94% and a positive return on equity of 1.83%. Evolent Health's revenue was down 31.3% on a year-over-year basis. During the same quarter last year, the business earned $0.30 earnings per share. Evolent Health has set its Q3 2025 guidance at EPS. As a group, analysts predict that Evolent Health, Inc will post 0.08 earnings per share for the current fiscal year.

Evolent Health Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.